A guide for functional analysis of BRCA1 variants of uncertain significance

Gael A. Millot, Marcelo A. Carvalho, Sandrine M. Caputo, Maaike P. G. Vreeswijk, Melissa A. Brown, Michelle Webb, Etienne Rouleau, Susan L. Neuhausen, Thomas V. O. Hansen, Alvaro Galli, Rita D. Brandao, Marinus J. Blok, Aneliya Velkova, Fergus J. Couch, Alvaro N. Monteiro*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

88 Citations (Web of Science)


Germline mutations in the tumor suppressor gene BRCA1 confer an estimated lifetime risk of 5680% for breast cancer and 1560% for ovarian cancer. Since the mid 1990s when BRCA1 was identified, genetic testing has revealed over 1,500 unique germline variants. However, for a significant number of these variants, the effect on protein function is unknown making it difficult to infer the consequences on risks of breast and ovarian cancers. Thus, many individuals undergoing genetic testing for BRCA1 mutations receive test results reporting a variant of uncertain clinical significance (VUS), leading to issues in risk assessment, counseling, and preventive care. Here, we describe functional assays for BRCA1 to directly or indirectly assess the impact of a variant on protein conformation or function and how these results can be used to complement genetic data to classify a VUS as to its clinical significance. Importantly, these methods may provide a framework for genome-wide pathogenicity assignment. Hum Mutat 33:15261537, 2012.
Original languageEnglish
Pages (from-to)1526-1537
JournalHuman Mutation
Issue number11
Publication statusPublished - Nov 2012


  • genetic testing
  • functional analysis
  • BRCA1
  • breast
  • ovarian
  • cancer
  • VUS

Cite this